查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726142

癌症免疫治疗市场规模、份额、趋势分析报告：按产品、最终用途、分布和细分市场预测，2025-2030 年

Cancer Immunotherapy Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

癌症免疫疗法市场的成长和趋势

根据Grand View Research, Inc.的最新报告，到2030年全球癌症免疫治疗市场规模预计将达到4,431.7亿美元，2025-2030年期间的复合年增长率为11.90%。

与其他癌症治疗方法相比，免疫疗法的针对性作用使其应用范围不断扩大，预计在预测期内其应用范围将会增加。此外，权威机构对肿瘤学新型免疫疗法的监管核准不断增加，预计也将进一步推动市场成长。例如，2021年10月，美国FDA核准了基因泰克公司的TECENTRIQ（Atezolizumab ）用于治疗非小细胞肺癌。

此外，肿瘤免疫疗法药物的强大产品平臺是推动市场强劲成长的关键驱动力之一。例如，阿斯特捷利康正在开发它用于小细胞肺部恶性肿瘤的一线治疗（III 期）。免疫肿瘤药物在提高存活率和降低毒性方面已显示出良好的效果。预计这些实验室发现将在未来几年增加新治疗方案的采用。

癌症治疗中联合治疗的日益普及也有望进一步推动免疫疗法的需求。联合治疗可以透过针对肿瘤微环境内的多种途径来增强免疫疗法的疗效。该公司主要致力于开发标靶治疗作为治疗癌症疾病的新方案。

免疫疗法的引入为乳癌、脑瘤、膀胱癌、淋巴瘤等恶性肿瘤的治疗提供了辅助选择。然而，与化疗、放射线治疗和手术相比，这种治疗方法的使用率极低。预计免疫疗法将在未来几年成为恶性肿瘤的主要治疗策略。癌症发病率的惊人上升刺激了全球对癌症治疗和其他治疗方法的研究合作。例如，2020 年 3 月，Astellas製药与 CytomX 合作扩大其下一代免疫肿瘤疗法产品线。此次合作有助于加强各公司的免疫肿瘤学产品组合。

此外，针对復发性和难治性恶性肿瘤的新型免疫疗法的开发和核准正在加速癌症免疫疗法市场的扩张。例如，2022年2月，强生旗下杨森製药公司宣布美国FDA核准CARVYKTI用于治疗四线或四线以上疗法治疗后的难治性多发性骨髓瘤。

癌症免疫疗法市场报告重点

  • 由于对单株抗体研发投入的不断增加，单株抗体领域将在 2024 年占据最大的市场占有率。
  • 由于肿瘤溶解病毒疗法和癌症疫苗对晚期恶性肿瘤患者俱有很高的临床效用，预计其子区隔将以最快的速度成长。
  • 从应用角度来看，肺癌由于其发病率不断上升以及免疫疗法在治疗中的应用日益广泛，在市场中占据主导地位。
  • 由于人们对前列腺癌的认识不断提高以及产品推出的数量不断增加，前列腺癌子区隔可能会出现最快的复合年增长率。
  • 由于医院对免疫治疗药物的需求不断增加以及癌症患者住院人数增加，医院诊所部门在 2024 年引领市场。
  • 由于医疗保健完善且未满足的医疗需求较高，预计亚太地区在预测期内将以最快的速度成长。
  • 市场的主要参与企业不断致力于开发新的治疗方法并扩大地理范围以增加其在全球市场的影响力。

目录

第一章调查方法与范围

第二章执行摘要

第三章癌症免疫疗法市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 癌症免疫治疗市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析

第四章 癌症免疫治疗市场：依产品分類的估价与趋势分析

  • 2024年及2030年的产品市场占有率
  • 细分仪表板
  • 全球癌症免疫疗法市场：产品展望
  • 2018-2030年市场规模、预测及趋势分析
    • 单株抗体
    • 免疫调节药物
    • 溶瘤病毒疗法和癌症疫苗

第五章 癌症免疫治疗市场：按应用的估计和趋势分析

  • 2024年及2030年的应用市场占有率
  • 细分仪表板
  • 全球癌症免疫治疗市场：应用前景
  • 2018-2030年市场规模、预测及趋势分析
    • 肺癌
    • 乳癌
    • 大肠直肠癌
    • 黑色素瘤
    • 摄护腺癌
    • 头颈癌
    • 卵巢癌
    • 胰臟癌
    • 其他的

第六章 癌症免疫治疗市场：依分布的估计与趋势分析

  • 2024年及2030年的二级市场占有率
  • 细分仪表板
  • 全球癌症免疫治疗市场：按分布展望
  • 2018-2030年市场规模、预测及趋势分析
    • 医院药房
    • 零售药局
    • 网路药局

第七章 癌症免疫疗法市场：依最终用途的估计和趋势分析

  • 2024 年及 2030 年最终用途市场占有率
  • 细分仪表板
  • 全球癌症免疫疗法市场：按最终用途分類的展望
  • 2018-2030年市场规模、预测及趋势分析
    • 医院和诊所
    • 癌症研究中心
    • 其他的

第八章癌症免疫治疗市场：按地区估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • 2024年主要企业市场占有率分析
    • Pfizer Inc.
    • AstraZeneca
    • Merck & Co., Inc
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Lilly
    • Johnson & Johnson Services, Inc
    • Immunocore, Ltd
Product Code: GVR-1-68038-693-6

Cancer Immunotherapy Market Growth & Trends:

The global cancer immunotherapy market size is expected to reach USD 443.17 billion by 2030, registering a CAGR of 11.90% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising adoption of the immunotherapy over other therapy options for cancer owing to its targeted action is anticipated to increase the adoption during the forecast period. Moreover, increasing regulatory approvals from authoritarian establishments for novel immunotherapy used for oncology is also expected to further fuel the market growth. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab), of Genentech, Inc for the treatment of NSCLC.

Moreover, the robust product pipeline of the immunotherapy medicines for oncology is one of the major driving factors for strong growth of the market. For instance, (phase-III), developed by AstraZeneca for the treatment of first-line stage small cell lung malignancy. Immuno-oncology agents have shown promising results with improved survival rates and less toxicity. Such clinical trial results are expected to increase the introduction of novel therapeutic options in the coming years.

Increasing adoption of the combination therapies to treat cancer is further expected to increase demand for the immunotherapy. Combination therapies target multiple pathways within the tumor microenvironment that can potentially increase effectiveness of the immunotherapeutic treatment. Companies are mainly emphasizing development of the targeted treatments as novel regimens for the oncology disorder treatment.

The introduction of immunotherapy has aided the treatment options for the malignancies of breast, brain, bladder, lymphomas, and others. Although the usage of this therapy is minimal as compared to chemotherapy, radiotherapy, and surgery. Immunotherapy is anticipated to emerge as the leading treatment strategy for the malignancies during the next few years. The alarming rise in oncology incidence rates has provoked global collaboration on oncology drugs and other therapies. For instance, in March 2020, Astellas Pharma and CytomX collaborated to expand pipeline of the next-generation Immuno-oncology treatments. This collaboration has helped companies to strengthen their immune-oncology portfolio.

Furthermore, development and approval of the novel immunotherapy treatments for relapsed and refractory malignancies are accelerating the cancer immunotherapy market expansion. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of CARVYKTI from the U.S. FDA for treatment of the refractory multiple myeloma after four or more lines of treatment.

Cancer Immunotherapy Market Report Highlights:

  • Monoclonal antibodies segment held the largest market share in 2024 owing to rising investments in the R&D of monoclonal antibodies
  • The oncolytic viral therapies & cancer vaccines sub-segment is anticipated to grow at the fastest rate owing to their greater clinical benefit to patients with advanced-stage malignancies
  • Based on application, lung cancer dominated the market owing to the rise in prevalence of the disease and increasing adoption of immunotherapy for the treatment
  • The prostate cancer sub-segment is likely to register the fastest CAGR due to the increasing awareness about prostate cancer and rising product launch
  • The hospitals & clinics segment led the market in 2024 owing to the increasing demand for immunotherapeutic medicines in hospitals and increasing hospitalization of cancer patients
  • Asia Pacific is expected to exhibit the fastest growth during the forecast period due to the growing establishment of healthcare, and high unmet medical needs
  • Key market players are continuously involved in the development of novel treatments and geographical expansion, in order to expand their footprint in the global market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. Distribution
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Application
    • 2.2.3. Distribution
    • 2.2.4. End Use
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of cancer
      • 3.2.1.2. Growing R&D activities by pharmaceutical companies
      • 3.2.1.3. Technological advancements and introduction of novel drugs
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Risk of side effects associated with the treatment
      • 3.2.2.2. High cost of therapy and unfavourable reimbursement scenario
  • 3.3. Cancer Immunotherapy Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Cancer Immunotherapy Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Monoclonal Antibodies
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Immunomodulators
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Oncolytic Viral Therapies and Cancer Vaccines
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Cancer Immunotherapy Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Cancer Immunotherapy Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Lung Cancer
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Breast Cancer
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Colorectal Cancer
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Melanoma
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Prostate Cancer
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Head and Neck Cancer
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Ovarian Cancer
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.8. Pancreatic Cancer
      • 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Cancer Immunotherapy Market: Distribution Estimates & Trend Analysis

  • 6.1. Distribution Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Cancer Immunotherapy Market by Distribution Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Hospital Pharmacy
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Retail Pharmacy
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Online Pharmacy
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Cancer Immunotherapy Market: End Use Estimates & Trend Analysis

  • 7.1. Distribution Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Cancer Immunotherapy Market by End Use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Hospitals & Clinics
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. Cancer Research Centers
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Others
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Cancer Immunotherapy Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.5. North America
    • 8.5.1. U.S.
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. Canada
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Europe
    • 8.6.1. UK
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Germany
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. France
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.4. Italy
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.5. Spain
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.6. Norway
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.7. Sweden
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/ reimbursement structure
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.8. Denmark
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/ reimbursement structure
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Japan
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. China
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. India
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Australia
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.5. South Korea
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/ reimbursement structure
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.6. Thailand
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/ reimbursement structure
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Brazil
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.8.2. Argentina
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9. MEA
    • 8.9.1. South Africa
      • 8.9.1.1. Key country dynamics
      • 8.9.1.2. Regulatory framework/ reimbursement structure
      • 8.9.1.3. Competitive scenario
      • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.2. Saudi Arabia
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/ reimbursement structure
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.3. UAE
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/ reimbursement structure
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.9.4. Kuwait
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/ reimbursement structure
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Pfizer Inc.
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. AstraZeneca
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Merck & Co., Inc
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. F. Hoffmann-La Roche Ltd
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Bristol-Myers Squibb Company
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Novartis AG
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Lilly
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Johnson & Johnson Services, Inc
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Immunocore, Ltd
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 5 North America Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 6 North America Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 8 U.S. Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 10 U.S. Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 14 Canada Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 17 Mexico Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 18 Mexico Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 23 Europe Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 25 Germany Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 26 Germany Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 27 Germany Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 29 UK Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 30 UK Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 31 UK Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 33 France Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 34 France Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 35 France Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 37 Italy Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 38 Italy Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 39 Italy Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 41 Spain Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 42 Spain Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 43 Spain Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 45 Denmark Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 46 Denmark Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 47 Denmark Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 49 Sweden Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 50 Sweden Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 51 Sweden Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 53 Norway Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 54 Norway Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 55 Norway Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 62 China Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 63 China Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 64 China Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 66 Japan Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 67 Japan Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 68 Japan Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 70 India Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 71 India Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 72 India Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 74 South Korea Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Korea Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 76 South Korea Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 78 Australia Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 79 Australia Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 80 Australia Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 82 Thailand Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 83 Thailand Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 84 Thailand Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 87 Latin America Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 88 Latin America Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 89 Latin America Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Brazil Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 91 Brazil Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 92 Brazil Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 93 Brazil Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 95 Argentina Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 97 Argentina Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA Cancer Immunotherapy market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 100 MEA Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 101 MEA Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 102 MEA Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 104 South Africa Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 105 South Africa Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 106 South Africa Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 112 UAE Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 113 UAE Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 114 UAE Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Cancer Immunotherapy market, by product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Cancer Immunotherapy market, by application, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Cancer Immunotherapy market, by distribution, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Cancer Immunotherapy market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Cancer Immunotherapy market: market outlook
  • Fig. 14 Cancer Immunotherapy competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Cancer Immunotherapy market driver impact
  • Fig. 20 Cancer Immunotherapy market restraint impact
  • Fig. 21 Cancer Immunotherapy market strategic initiatives analysis
  • Fig. 22 Cancer Immunotherapy market: Product movement analysis
  • Fig. 23 Cancer Immunotherapy market: Product outlook and key takeaways
  • Fig. 24 Monoclonal Antibodies market estimates and forecast, 2018 - 2030
  • Fig. 25 Immunomodulators market estimates and forecast, 2018 - 2030
  • Fig. 26 Oncolytic Viral Therapies and Cancer Vaccines market estimates and forecast, 2018 - 2030
  • Fig. 27 Cancer Immunotherapy Market: Application movement Analysis
  • Fig. 28 Cancer Immunotherapy market: Application outlook and key takeaways
  • Fig. 29 Lung Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 30 Breast Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 31 Colorectal Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 32 Melanoma market estimates and forecasts, 2018 - 2030
  • Fig. 33 Prostate Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 34 Head and Neck Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 35 Ovarian Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 36 Pancreatic Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030
  • Fig. 38 Cancer Immunotherapy market: Distribution movement analysis
  • Fig. 39 Cancer Immunotherapy market: Distribution outlook and key takeaways
  • Fig. 40 Hospital Pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 41 Retail Pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 42 Online Pharmacy market estimates and forecasts, 2018 - 2030
  • Fig. 43 Cancer Immunotherapy market: End Use movement analysis
  • Fig. 44 Cancer Immunotherapy market: End Use outlook and key takeaways
  • Fig. 45 Hospitals & Clinics market estimates and forecasts, 2018 - 2030
  • Fig. 46 Cancer Research Centers market estimates and forecasts, 2018 - 2030
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030
  • Fig. 48 Global Cancer Immunotherapy market: Regional movement analysis
  • Fig. 49 Global Cancer Immunotherapy market: Regional outlook and key takeaways
  • Fig. 50 Global Cancer Immunotherapy market share and leading players
  • Fig. 51 North America market share and leading players
  • Fig. 52 Europe market share and leading players
  • Fig. 53 Asia Pacific market share and leading players
  • Fig. 54 Latin America market share and leading players
  • Fig. 55 Middle East & Africa market share and leading players
  • Fig. 56 North America: SWOT
  • Fig. 57 Europe SWOT
  • Fig. 58 Asia Pacific SWOT
  • Fig. 59 Latin America SWOT
  • Fig. 60 MEA SWOT
  • Fig. 61 North America, by country
  • Fig. 62 North America
  • Fig. 63 North America market estimates and forecasts, 2018 - 2030
  • Fig. 64 U.S.
  • Fig. 65 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 66 Canada
  • Fig. 67 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 68 Mexico
  • Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 70 Europe
  • Fig. 71 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 72 UK
  • Fig. 73 UK market estimates and forecasts, 2018 - 2030
  • Fig. 74 Germany
  • Fig. 75 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 76 France
  • Fig. 77 France market estimates and forecasts, 2018 - 2030
  • Fig. 78 Italy
  • Fig. 79 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 80 Spain
  • Fig. 81 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 82 Denmark
  • Fig. 83 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 84 Sweden
  • Fig. 85 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 86 Norway
  • Fig. 87 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 88 Asia Pacific
  • Fig. 89 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 90 China
  • Fig. 91 China market estimates and forecasts, 2018 - 2030
  • Fig. 92 Japan
  • Fig. 93 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 94 India
  • Fig. 95 India market estimates and forecasts, 2018 - 2030
  • Fig. 96 Thailand
  • Fig. 97 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 98 South Korea
  • Fig. 99 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 100 Australia
  • Fig. 101 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 102 Latin America
  • Fig. 103 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 104 Brazil
  • Fig. 105 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 106 Argentina
  • Fig. 107 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 108 Middle East and Africa
  • Fig. 109 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 110 South Africa
  • Fig. 111 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 112 Saudi Arabia
  • Fig. 113 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 114 UAE
  • Fig. 115 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 116 Kuwait
  • Fig. 117 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 118 Market share of key market players- Cancer Immunotherapy market